Inhibition of iNOS induces antidepressant-like effects in mice: Pharmacological and genetic evidence


Autoria(s): Montezuma, Karina; Biojone, Caroline; Lisboa, Sabrina F.; Cunha, Fernando Q.; Guimaraes, Francisco S.; Joca, Samia R. L.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

16/09/2013

16/09/2013

2012

Resumo

Recent evidence has suggested that systemic administration of non-selective NOS inhibitors induces antidepressant-like effects in animal models. However, the precise involvement of the different NOS isoforms (neuronal-nNOS and inducible-iNOS) in these effects has not been clearly defined yet. Considering that mediators of the inflammatory response, that are able to induce iNOS expression, can be increased by exposure to stress, the aim of the present study was to investigate iNOS involvement in stress-induced behavioral consequences in the forced swimming test (FST), an animal model sensitive to antidepressant drugs. Therefore, we investigated the effects induced by systemic injection of aminoguanidine (preferential iNOS inhibitor), 1400W (selective iNOS inhibitor) or n-propyl-L-arginine (NPA, selective nNOS inhibitor) in mice submitted to the FST. We also investigated the behavior of mice with genetic deletion of iNOS (knockout) submitted to the FST. Aminoguanidine significantly decreased the immobility time (IT) in the FST. 1400W but not NPA, when administered at equivalent doses considering the magnitude of their Ki values for iNOS and nNOS, respectively, reduced the IT, thus suggesting that aminoguanidine-induced effects would be due to selective iNOS inhibition. Similarly, iNOS KO presented decreased IT in the FST when compared to wild-type mice. These results are the first to show that selective inhibition of iNOS or its knockdown induces antidepressant-like effects, therefore suggesting that iNOS-mediated NO synthesis is involved in the modulation of stress-induced behavioral consequences. Moreover, they further support NO involvement in the neurobiology of depression. This article is part of a Special Issue entitled 'Anxiety and Depression'. (C) 2011 Elsevier Ltd. All rights reserved.

FAPESP

FAPESP [2007/03685-3, 2009/18372-6]

CNPq

CNPq

Identificador

NEUROPHARMACOLOGY, OXFORD, v. 62, n. 1, Special Issue, pp. 485-491, JAN, 2012

0028-3908

http://www.producao.usp.br/handle/BDPI/33393

10.1016/j.neuropharm.2011.09.004

http://dx.doi.org/10.1016/j.neuropharm.2011.09.004

Idioma(s)

eng

Publicador

PERGAMON-ELSEVIER SCIENCE LTD

OXFORD

Relação

NEUROPHARMACOLOGY

Direitos

closedAccess

Copyright PERGAMON-ELSEVIER SCIENCE LTD

Palavras-Chave #STRESS #DEPRESSION #NITRIC OXIDE #INOS #NNOS #FORCED SWIMMING TEST #HIPPOCAMPUS #NITRIC-OXIDE SYNTHASE #FORCED SWIMMING TEST #LEARNED HELPLESSNESS DEVELOPMENT #STRESS-INDUCED DEPRESSION #SKELETAL-MUSCLE #5-HT1A RECEPTORS #NMDA RECEPTOR #NOS INHIBITOR #BRAIN CORTEX #ANIMAL-MODEL #ÓXIDO NÍTRICO #ANTIDEPRESSIVOS #DEPRESSÃO #ESTRESSE #NEUROSCIENCES #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion